Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor family that is implicated in apoptosis, proliferation, migration, and inflammation. We describe our findings showing that TWEAK mediated the differentiation of RAW264. 
1
/TNF receptor (TNFR) superfamily are important regulators of diverse processes, including apoptosis, cellular proliferation, immune responses, and bone remodeling (1) . The receptors in this family usually share homology in the cysteine-rich repeats found in their extracellular domains. However, no significant homology is found in their cytoplasmic domains, with the exception of death domains within some receptors that are involved in apoptotic signaling. TNFRs thus can be categorized into three classes: transmembrane receptors without death domains, transmembrane receptors with death domains, and decoy receptors that either have truncated cytoplasmic domains or are soluble secreted receptors.
TNFRs themselves do not possess intrinsic kinase activity; instead, they transmit signals by recruiting various adaptor molecules that bind to their cytoplasmic domains (2) (3) (4) . The types of adaptor molecules recruited and the signaling pathways activated differ, depending on the specific receptor involved and the context of the target cell. Receptors with death domains generally recruit adaptor proteins such as the TNFRassociated death domain, Fas-associated death domain, and receptor interactive protein 1, ultimately leading to the recruitment of caspases that cause apoptotic cell death. A second major group of adaptor proteins is the TNFR-associated factors (TRAFs), which generally activate kinases of the mitogen-activated protein kinase (MAPK) family and the transcription factor nuclear factor-B (NF-B) (2) (3) (4) .
TWEAK (TNFSF12) is a newly discovered member of the TNF family that was first described as a weak inducer of apoptosis (5) . Indeed, TWEAK induces apoptosis or necrosis in certain cell lines, but in most cells, its ability to induce cell death depends on the addition of interferon-␥ or cyclohexamide (5) (6) (7) (8) (9) . Overall, the physiological roles of TWEAK remain largely unknown. TWEAK was shown to play a role in monocyte cytotoxicity stimulated by interferon-␥ and to mediate monocyte death induced by autologous lupus T cells (10, 11) . Interestingly, TWEAK has also been implicated in angiogenic regulation by stimulating endothelial cell growth and angiogenesis in rat corneas (12, 13) . Finally, TWEAK also contributes to pro-inflammatory reactions, including the up-regulation of adhesion molecules and the secretion of cytokines (14 -17) .
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biological effects in cells lacking DR3 (6, 7, 18) . Recently, an expression cloning technique identified a receptor for TWEAK (TweakR) (19) , which was previously cloned as a fibroblast growth factor-inducible gene (Fn14) (20) . The classification of Fn14 as a member of the TNF family was not considered at first because of its lack of homology with other TNFRs. Retrospectively, however, a limited homology was found with a single cysteine-rich repeat in the extracellular domain and a putative TRAF-binding motif in the intracellular domain.
Little progress had been made in studying TWEAK-induced signal transduction pathways and the role that Fn14/TweakR plays in mediating TWEAK-generated signals. The ability of Fn14/TweakR to serve as a receptor for TWEAK was confirmed when it was shown to stimulate NF-B activation upon TWEAK treatment and to mediate the pro-inflammatory and cell death effects of TWEAK (9, 14, 21) . The cytoplasmic domain of Fn14/TweakR, which is only 28 amino acids long, was shown to interact with various TRAF molecules (TRAF1, -2, -3, and -5) (19, 21, 22) . Moreover, dominant-negative TRAF2 or TRAF5 molecules were shown to inhibit NF-B activation in response to TWEAK (14, 22) . In addition, TWEAK was shown to activate caspases 3 and 8 in human oral squamous cell carcinoma HSC3 cells and human colon adenocarcinoma HT-29 cells that undergo TWEAK-induced apoptosis, although the receptor mediating this effect was not addressed (6) .
In the present study, we discovered a novel function of TWEAK: the differentiation of RAW264.7 (RAW) monocyte/ macrophage cells into tartrate-resistant acid phosphatase (TRAP)-positive, multinuclear osteoclasts. Interestingly, we also found evidence that Fn14/TweakR is not responsible for mediating this biological function. Thus, we propose that a second TWEAK receptor, TweakR2, exists. Moreover, we show that TweakR2 and Fn14/TweakR induce differential activation of signaling pathways.
EXPERIMENTAL PROCEDURES
Cells and Antibodies-Cells were obtained from the American Type Culture Collection. RAW264.7 cells were maintained in Dulbecco's modified Eagle's/Ham's F12 medium supplemented with 10% heat-inactivated fetal bovine serum and 1% antibiotics (Invitrogen). HT-29 cells were grown in RPMI 1640 medium with 10% fetal bovine serum and 1% antibiotics.
We purchased anti-inhibitor of kappa B alpha (IB␣) and anti-c-Jun N-terminal kinase (JNK) antibodies from Santa Cruz Biotechnology, Inc.; anti-phospho-p42/p44 MAPK from Cell Signaling Technology; TWEAK-neutralizing antibodies from Cell Sciences, Inc.; and receptor activator of NF-B ligand (RANKL)-neutralizing antibodies from Leinco Technologies (St. Louis, MO). Phycoerythrin (PE)-labeled antiFn14/TweakR antibodies (PE-ITEM-4) and unlabeled ITEM-4 (Fn14/ TweakR-neutralizing antibodies) were purchased from eBiosciences. Chromatographically purified mouse IgG was purchased from Zymed Laboratories Inc.. Fn14:Fc (Fn14 fused to the Fc region of human IgG 1 ) was purchased from Alexis Corporation; and recombinant human osteoprotegerin (OPG) was purchased from R&D Systems.
Construct Generation and Fusion Protein Purification-A plasmid containing the cDNA of human TWEAK was generously provided by Dr. B. Aggarwal (The University of Texas M. D. Anderson Cancer Center, Houston, TX). To generate GST-TWEAK, a cDNA fragment of TWEAK (amino acids 97-250) was amplified by PCR and was inserted into pGEX-KG, in frame with GST, using the XbaI/XhoI sites. To purify GST-TWEAK, pGEX-KG-TWEAK was transformed into BL-21 Escherichia coli cells (Novagen). Cells were grown for 2 h at 37°C, and protein expression was induced by exposure to 500 M isopropyl-␤-Dthiogalactopyranoside at 20°C for 4 h. Cells were then harvested and lysed in lysis buffer (50 mM Tris, pH 8.2, 300 mM NaCl, 10% glycerol, 1 mM dithiothreitol (DTT), 10 M aprotinin, and 10 M leupeptin) containing 100 g/ml lysozyme for 30 min on ice. Lysates were sonicated and centrifuged at 40,000 rpm for 1 h at 4°C. Glutathione agarose beads (Sigma-Aldrich, Inc.) were used to pull down GST-TWEAK. Beads were washed in lysis buffer, next with a high-salt buffer (lysis buffer containing 1 M NaCl), and finally with 50 mM Tris, pH 8.2, 150 mM NaCl, and 1 mM DTT. GST-fusion proteins were eluted with 20 mM glutathione and dialyzed overnight at 4°C in 50 mM Tris, pH 8.2, 150 mM NaCl, and 1 mM DTT. Purified GST-proteins were stored in small aliquots at Ϫ30°C in 10% glycerol.
pcDNA3.1-RANKL, an expression vector with full-length murine RANK, was generously provided by Y. Choi (Rockefeller University, New York, NY). To generate a bacterial expression vector for His-RANKL, mRANK (amino acids 157-316) was amplified from pcDNA3.1-RANKL; the resulting PCR product was digested with HindIII/NotI and was finally ligated in-frame with hemagglutinin (N-terminal) and histidine (C-terminal) tags into the expression vector pHB6 (Roche Applied Science). His-RANKL was purified using nickel-affinity chromatography, essentially using the same procedure as described for the purification of GST-fusion proteins (23) .
RAW Cell Differentiation Assay-RAW cells were plated at a density of 10,000 cells per well in a 24-well plate or 3,500 cells per well in a 48-well plate and allowed to attach overnight. Ligands were added the next day, and cells were allowed to differentiate for 4 days. Cells were then stained for TRAP, an osteoclast-specific marker, using a leukocyte acid phosphatase kit (Sigma-Aldrich, Inc.) according to the manufacturer's instructions. Osteoclasts were defined as large cells that contained more than five nuclei and were TRAP-positive.
Bone Resorption Assay-RAW cells were plated at a density of 1000 cells per well on an artificial bone slide (BD Biosciences) and allowed to attach overnight. Ligands and/or OPG were added the next day. After 6 days, the medium was removed, the slide was fixed in bleach solution containing 5.2% NaCl for 5 min at room temperature, and washed in distilled H 2 O before examination by light microscopy.
Kinase Assay-JNK activity was analyzed using GST-Jun (amino acids 1-79) as a substrate as described previously (24) . Briefly, RAW cells were plated at 1 ϫ 10 6 cells per well in a 6-well dish and treated as indicated. Cells were harvested and washed three times in ice-cold phosphate-buffered saline (PBS) and were lysed for 30 min on ice in a buffer containing 20 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM DTT, and protease and phosphatase inhibitors. Lysates were spun for 25 min at 13,000 rpm and 4°C in a microcentrifuge, and the amount of protein in each sample was determined using a Bradford assay (Bio-Rad). Endogenous JNK was immunoprecipitated using anti-JNK antibodies. Beads were then washed three times in lysis buffer and once in a low-salt buffer containing 20 mM Tris, pH 7.4, and 25 mM NaCl. The kinase assay was performed in a 2ϫ reaction mix containing 50 mM Tris, pH 7.9, 40 mM MgCl 2 , 2 mM DTT, 2 g of GST-Jun (amino acids 1-79), and 10 Ci of [␥- 32 P]ATP at 30°C for 15 min. Samples were analyzed using a 10% SDS-PAGE. Phosphorylation of GST-Jun was detected using autoradiography.
Western Blot Analysis-Cells were lysed in 20 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM DTT, and protease and phosphatase inhibitors for 30 min on ice and spun at 13,000 rpm in a microcentrifuge for 25 min at 4°C. To prepare cytosolic extracts, cells were suspended in 10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and protease and phosphatase inhibitors. Cells were allowed to swell on ice for 30 min, after which 10% Nonidet P-40 was added to a final concentration of 3%. Samples were vortexed for 3 s, centrifuged for 3 min at 4°C, and supernatant (cytosolic fraction) was transferred to a clean tube. Proteins were separated using SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked in 5% milk in PBS with 0.1% Tween 20, incubated with the appropriate antibodies according to the manufacturer's recommendation and subjected to enhanced chemiluminescence analysis.
Flow Cytometry-Samples of 1 ϫ 10 6 RAW or HT-29 cells were incubated in 0.1 ml of PBS containing 2% fetal bovine serum together with 0.5 g of either PE-ITEM-4 or its isotype control (PE-mIgG2b/ ; BD Pharmingen) for 2 h on ice in the dark. Samples were then washed twice with PBS and resuspended in 0.5 ml of PBS. Cells were analyzed on a FACScan flow cytometer (BD Biosciences) with Cell Quest software.
RESULTS

TWEAK Induces Differentiation of RAW Cells into
Osteoclasts-To study TWEAK-induced signal transduction, we screened for cells that responded to TWEAK. We found that treatment of RAW cells with TWEAK resulted in a dose-dependent differentiation of RAW cells into large, multi-nucleated, TRAP-positive osteoclasts (Fig. 1, A and B) . To test whether TWEAK-induced osteoclasts were functional and able to resorb bone, RAW cells were plated on an artificial bone matrix and treated with either RANKL or TWEAK. TWEAKinduced osteoclast activation, like that of RANKL, resulted in pit formation in the artificial bone matrix (Fig. 1C) . Hence, TWEAK induced the differentiation of RAW cells into functional, bone-resorbing osteoclasts.
The differentiation induced by TWEAK was very similar to that induced by the osteoclastic factor RANKL (Fig. 1, A and  B) . To confirm that the osteoclastic effect of TWEAK was direct and not mediated by RANKL, TWEAK was combined with OPG, a decoy receptor for RANKL that inhibits its activity. TWEAK induced both RAW cell differentiation into osteoclasts and bone resorption in the presence of OPG, whereas the osteoclastic effect of RANKL was blocked completely by OPG (Figs.  1C and 2A) . No inhibition of TWEAK-induced osteoclasts was observed even when a higher concentration of OPG was used (500 ng/ml OPG; Fig. 1C and data not shown) . In addition, TWEAK-neutralizing antibodies, but not RANKL-neutralizing antibodies, inhibited TWEAK-induced osteoclast formation in a dose-dependent manner (Fig. 2B) . Conversely, RANKL-induced osteoclastogenesis was blocked by RANKL-neutralizing antibodies but not by TWEAK-neutralizing antibodies (Fig.  2B) . These assays confirmed that TWEAK induced the differentiation of RAW cells into TRAP-positive osteoclasts in a RANKL-independent manner.
Fn14/TweakR was recently identified as a receptor for TWEAK (19) . We confirmed the interaction between TWEAK and Fn14/TweakR using both full-length Fn14/TweakR and the soluble extracellular domain of Fn14/TweakR, Fn14:Fc (data not shown). Fn14:Fc was previously used to confirm the involvement of TWEAK in several other biological processes, including the migration of endothelial cells, astrocyte proliferation, and fibroblast growth factor-2-stimulated angiogenesis (17, 19 ). Hence, we tested the ability of Fn14:Fc to inhibit TWEAK-induced osteoclast differentiation in RAW cells. RAW cells were treated with either TWEAK or RANKL in the presence of increasing concentrations of Fn14:Fc and were stained for TRAP expression after 4 days. Fn14:Fc inhibited, in a dose-dependent manner, the formation of osteoclasts induced by TWEAK but not those induced by RANKL. Because Fn14:Fc acts by binding to TWEAK and inhibiting it from interacting with its receptor, this confirmed that the differentiation of RAW cells into osteoclasts was mediated by TWEAK (Fig. 2C) .
RAW Cells Do Not Express Fn14/TweakR-Next, we tested whether RAW cells expressed Fn14/TweakR. HT-29 cells were used as a positive control (9) and expressed Fn14/TweakR as determined by cell surface staining with PE-ITEM-4, a monoclonal anti-Fn14/TweakR antibody (Fig. 3A, top histograms) . In addition, expression of Fn14/TweakR was detected on mouse NIH3T3 cells, suggesting that ITEM-4 antibodies recognize both mouse and human Fn14/TweakR (data not shown). Interestingly, no expression of Fn14/TweakR was detected on RAW cells by flow cytometry analysis (Fig. 3A, bottom histograms) or
FIG. 1. TWEAK induces dose-dependent differentiation of RAW cells into functional osteoclasts.
A, RAW cells were left untreated (control) or treated with 500 ng/ml GST-TWEAK, 500 ng/ml GST, or 100 ng/ml RANKL for 4 days. Cells were stained for TRAP expression. Photos were taken under a microscope at 10ϫ magnification. B, RAW cells were treated with the indicated concentrations of GST-TWEAK or RANKL, and the number of osteoclasts per well was counted after 4 days. Bars represent the mean of at least three independent experiments, and error bars indicate standard deviation of the mean. C, RAW cells were plated on an artificial bone matrix slide and were treated with 500 ng/ml TWEAK, 100 ng/ml RANKL, or 500 ng/ml OPG, as indicated. After 6 days, the slide was fixed, and resorption was determined by examining pit formation under a light microscope (10ϫ magnification).
by Western blot analysis with anti-Fn14/TweakR antibodies (data not shown). Consistent with the lack of Fn14/TweakR expression on RAW cells, Fn14/TweakR-neutralizing antibodies (ITEM-4) did not inhibit TWEAK-induced differentiation of RAW cells (Fig. 3B) . These results suggest that a second receptor for TWEAK, other than Fn14/TweakR, exists on RAW cells. We hereafter refer to this receptor as TweakR2.
Differential Activation of Signaling Pathways by Fn14/ TweakR and TweakR2-To examine the signaling pathways that are activated by Fn14/TweakR and TweakR2, we compared stimulation of the NF-B, MAPK, and JNK pathways both in HT-29 cells, which express endogenous Fn14/TweakR, and in RAW cells, which express TweakR2. NF-B activation was monitored by the degradation of IB␣, an NF-B inhibitor.
Once IB␣ is degraded, NF-B is free to pass into the nucleus and bind to its specific response elements (25) . As shown in Fig.  4A , TWEAK stimulated IB␣ degradation in both HT-29 and RAW cells, indicating that both Fn14/TweakR and TweakR2 activate the NF-B signaling pathway. To verify that each of the cell lines express only one of the receptors and not both, we used Fn14/TweakR-neutralizing ITEM-4 antibodies. Indeed, ITEM-4, but not control mouse IgG antibodies, completely inhibited TWEAK-induced IB␣ degradation in HT-29 cells. These results confirmed that in HT-29 cells TWEAK-induced signaling was mediated only via Fn14/TweakR and not through TweakR2. In contrast, ITEM-4 antibodies had no effect on TWEAK-induced MAPK activation in RAW cells, suggesting that the signaling in these cells was not mediated via Fn14/
FIG. 2. TWEAK-induced differentiation of RAW cells into osteoclasts is RANKL-independent.
A, RAW cells were treated with 750 ng/ml TWEAK, 100 ng/ml RANKL, or 100 ng/ml OPG for 4 days, as indicated. Cells were stained for TRAP expression, and the number of positive osteoclasts in each sample was counted. B, RAW cells were left untreated (control) or treated with 500 ng/ml TWEAK or 100 ng/ml RANKL and with increasing concentrations (0.25, 0.5, or 1 g/ml) of either TWEAK-or RANKL-neutralizing antibodies. After 4 days, cells were stained for TRAP expression, and the number of osteoclasts per well was counted. C, RAW cells were treated with 500 ng/ml TWEAK or 100 ng/ml RANKL in the presence of increasing concentrations of Fn14:Fc (0.25, 1.25, and 2.5 g/ml) for 4 days and stained for TRAP expression. Error bars indicate standard deviation of the mean.
TweakR. Hence, this indicated that each cell line expresses only one type of receptor and not both.
To determine whether MAPK is activated by Fn14/TweakR and TweakR2, we monitored activation of the p44 (ERK1) and p42 (ERK2) proteins by Western blotting with phospho-specific anti-p42/p44 antibodies. A time-course analysis with antibodies that specifically recognize the phosphorylated forms of these proteins revealed that TWEAK induced the phosphorylation of MAPK after 10 -15 min of stimulation in RAW cells (Fig. 4B) . ITEM-4 antibodies did not inhibit MAPK activation, verifying that Fn14/TweakR is not responsible for mediating the response in RAW cells. In contrast, TWEAK treatment of HT-29 cells expressing endogenous Fn14/TweakR resulted in only a weak activation of MAPK (Fig. 4B) . We have repeated these experiments numerous times and got either weak activation or no activation of MAPK in HT-29 cells. To confirm that low TWEAK concentrations were not preventing us from detecting significant MAPK activation in HT-29 cells, we increased the concentrations from 500 to 1500 ng/ml. However, even at the higher TWEAK concentration, the activation of MAPK was still minimal (Fig. 4B and data not shown) . Treatment of HT-29 cells with epidermal growth factor induced MAPK activation within 5 min, confirming that the MAPK pathway was intact in these cells.
We next examined the ability of TWEAK to activate the JNK signaling pathway in RAW and HT-29 cells. TWEAK treatment resulted in JNK activation within 10 -15 min in both cell lines, as detected by an in vitro kinase assay using GST-Jun as a substrate (Fig. 4C) . This suggested that both Fn14/TweakR and TweakR2 activate the JNK pathway.
DISCUSSION
Our findings have revealed the presence of a second receptor for TWEAK, which we refer to as TweakR2, that mediated the differentiation of RAW cells into osteoclasts. Considering the wide range of TWEAK's biological effects and the short (28 amino acids) cytoplasmic domain of Fn14/TweakR, it is conceivable that at least one additional receptor is involved in TWEAK signaling. The ability to bind to more than one receptor and elicit diverse responses is common among members of the TNF family and previously has been shown for numerous TNF ligands, including TNF, TRAIL, BLYS, APRIL, LT␣, and LIGHT (1) .
Accumulating evidence supports a role for Fn14/TweakR in mediating TWEAK's effects (9, 14, 21) . For example, the involvement of Fn14/TweakR in cell death and inflammatory processes was shown by the use of Fn14/TweakR-neutralizing antibodies (9, 14) . In other TWEAK-induced responses, such as angiogenesis, there is no direct evidence to suggest the involvement of Fn14/TweakR. In fact, the involvement of Fn14/ TweakR in angiogenesis was based on indirect experiments using Fn14/TweakR:Fc, which blocks TWEAK's action, but not Fn14/TweakR itself. However, Fn14/TweakR-neutralizing antibodies that specifically block Fn14/TweakR were not tested (19) .
We present two lines of evidence to support the existence of TweakR2. First, in the absence of Fn14/TweakR, TWEAK activated signaling pathways, such as NF-B, MAPK, and JNK, and caused RAW cells to differentiate into functional osteoclasts. Second, Fn14/TweakR-neutralizing antibodies did not inhibit RAW cell differentiation. Hence, our data strongly support the hypothesis of an additional TWEAK receptor.
Based on our results, both Fn14/TweakR and TweakR2 activated NF-B, MAPK, and JNK, although Fn14/TweakR only weakly activated MAPK (Fig. 4) . In support of our findings, TWEAK weakly induced MAPK activation in 293 cells transiently transfected with Fn14/TweakR (data not shown). However, in a series of reporter assays using MAPK family responsive elements (activator protein 1, cAMP response element, and serum response element), transfection of Fn14/TweakR into NIH3T3 cells did not induce activation of MAPK, JNK, or p38 MAPK (21) . In light of the interaction between Fn14/TweakR and TRAFs and the paradigm of TRAF-mediated activation of NF-B and the MAPK family (26) , it is surprising that Fn14/ TweakR only weakly activated the MAPK pathway in HT-29 FIG. 3 . RAW cells do not express Fn14/TweakR. A, HT-29 or RAW cells were labeled with either an isotype control PE-mIgG2b/ antibody or an antibody against Fn14/TweakR (PE-ITEM-4). Cells were analyzed using a FACScan flow cytometer and Cell Quest software to detect the expression of the Fn14/TweakR protein on the cell surface. B, RAW cells were pre-incubated with 1 g/ml Fn14/TweakR-neutralizing antibodies (ITEM-4) for 30 min and then treated with 750 ng/ml TWEAK or 100 ng/ml RANKL for 4 days. Cells were stained for TRAP expression, and the number of positive osteoclasts in each sample was counted. cells (Fig. 4) and did not activate it in NIH3T3 cells overexpressing Fn14/TweakR (21) .
The ability of Fn14/TweakR and TweakR2 to differently stimulate signaling pathways may suggest that the two receptors use distinct intracellular adaptor/signaling molecules to transmit their signals. Alternatively, it is possible that the recruitment of specific signaling molecules depends on their presence or concentration in a certain cell type. We believe it is unlikely that the differential activation of signaling pathways stems from the amount of receptors expressed because both receptors were able to induce NF-B activation to a similar extent. The differential activation of signaling pathways by Fn14/TweakR and TweakR2 probably reflects the various roles that these receptors play in mediating TWEAK's effects.
TWEAK previously has been found to induce a wide array of cellular responses, including proliferation, migration, and induction of cell death. Our findings suggest that TWEAK is a potentially novel osteoclastic factor that is independent of RANKL. Although TWEAK and RANKL were similar in terms of their osteoclastic effects in RAW cells, we did not find that TWEAK induced the differentiation of osteoclasts from a primary human monocyte precursor (data not shown). Perhaps RAW cells, which are further down the differentiation pathway, can differentiate more easily than human monocytes. Although RAW cells require only RANKL (or only TWEAK) for their differentiation (27) , primary human monocytes also require macrophage-colony stimulating factor (28) . It is possible that factors other than macrophage-colony stimulating factor are required to drive the TWEAK-induced differentiation of human monocytes.
The finding that knockout mice deficient in RANK or RANKL expression lack osteoclasts argues against a role for TWEAK in this model system (29 -31) . However, TNF-␣, another TNF family member with potential osteoclastic effects, also was unable to substitute for RANK/RANKL in knockout mice (32, 33) . Hence, it is possible that factors such as TWEAK and TNF-␣ exert their osteoclastic effects only under certain pathological conditions. Interestingly, TWEAK and RANKL A, RAW and HT-29 cells were either left untreated or were pretreated with ITEM4 (1 g/ml) or mouse IgG (mIgG, 1 g/ml) for 1 h, followed by the addition of 1500 ng/ml GST-TWEAK for the indicated times. Cytosolic extracts were prepared and samples were analyzed using Western blot with anti-IB␣ antibodies. B, RAW cells were treated as described in A. HT-29 cells were treated with either 1500 ng/ml GST-TWEAK or 10 ng/ml epidermal growth factor for the indicated times. Cellular extracts were probed with a phospho-specific p42/p44 antibody. C, anti-JNK antibodies were used to immunoprecipitate JNK from either RAW cells treated with TWEAK (300 ng/ml) or HT-29 cells (750 ng/ml). An in vitro kinase assay was performed with GST-Jun as the substrate. Samples were analyzed using a 10% SDS-PAGE and autoradiography. exhibited additive osteoclastic effects when used in combination in RAW cells (data not shown) and not synergistic effects, as seen with TNF-␣ and RANKL (34) . This additive response is supported by our findings that TWEAK activated downstream signaling pathways in RAW cells similar to those activated by RANKL, including MAPK, JNK, and NF-B (35, 36) .
Fn14/TweakR, originally identified as a growth factor-inducible gene, was recently added to the growing family of TNFRs (19, 20) . Our data confirm that Fn14/TweakR is a functional TWEAK receptor, and we suggest that a second TWEAK receptor, TweakR2, exists. We propose that each receptor will carry an overlapping, but distinct, set of biological responses. Cloning TweakR2 and identifying the adaptor molecules and signaling pathways employed by TweakR2 and Fn14/TweakR will provide more clues to unravel the function of TWEAK.
